Novozymes half-life extension tech used in GSK's GLP-1 contender 01-Apr-2014 By Dan Stanton GSK’s Eperzan (albiglutide) has become the first approved drug to use the Veltis half-life extension technology and, according to Novozymes, may make it a strong competitor in the GLP-1 agonist market.
Novo Nordisk buys rights to Caisson’s drug-extending biotech 18-Mar-2014 By Fiona BARRY Caisson Biotech has licensed its drug-extending technology for injectables to Novo Nordisk.
Novo Nordisk invests $100m in diabetes pipeline purification plant 18-Mar-2014 By Dan Stanton Novo Nordisk has invested 550m Danish Kroner ($100m) to expand a purification plant in Denmark for its diabetes biodrug pipeline.
Novo Nordisk takes Adimab's mAb tech in-house 27-Sep-2013 By Dan Stanton Novo Nordisk says Adimab’s yeast-based monoclonal antibody (mAb) technology will significantly upgrade its discovery programme.
Sanofi Buys Freeslate’s Biologics Formulation System 04-Sep-2013 By Zachary Brennan Sanofi Pasteur has purchased Freeslate’s biologics formulation system to accelerate its vaccine research and protein development programmes.
Manufacturing Concerns Halt US Approval for Novo Nordisk's Factor XIII 14-Aug-2013 By Dan Stanton Novo Nordisk says it has received a complete response letter for its recombinant factor XIII drug citing manufacturing concerns at a Danish facility.
New Software Helping Biogen, Novo Nordisk Increase Stability of Biopharmaceuticals 07-Aug-2013 By Zachary Brennan Both Biogen and Novo Nordisk have licensed a new software program to increase the stability of their protein-based biopharmaceuticals.
West eyes growth from FDA biosimilar delivery flexibility 28-May-2012 By Nick Taylor West Pharmaceutical Services expects significant growth from biosimilars as manufacturers use novel delivery devices as a “key differentiator”.
Novo Nordisk warns FDA of biosimilar delivery safety fears 17-Apr-2012 By Nick TAYLOR Novo Nordisk has told the FDA allowing alternative delivery devices for biosimilars creates “significant safety implications”.
Novo Nordisk gets transparent on bioethics Novo Nordisk gets transparent on bioethics 05-Jul-2007 By Emilie Reymond Biopharma company Novo Nordisk has launched a new website dedicated to bioethics which it claims is the first of its kind in the industry.